Close
Close
Treatment News

Hyperion Therapeutics to Present at the 26th Annual Roth Conference

2.5
2.5 from 4 votes
Tuesday, March 11, 2014

Learn more about:

Clinical Trials

BRISBANE, Calif., - Hyperion Therapeutics(Nasdaq:HPTX) announced that the company is scheduled to present at the 26thAnnual Roth Conference on Tuesday, March 11, 2014 at 10:30 a.m. PT.

Jeffrey S. Farrow, chief financial officer, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion's website athttp://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. For more information, please visit www.hyperiontx.com.

CONTACT: Myesha Edwards

         Assoc. Dir., Corporate Communications and Investor Relations

         (650) 745-7829
Source: Hyperion Therapeutics
2.5
2.5 from 4 votes
Free Newsletter
Related Videos
by Abidemi Uruejoma
40 views
by Abidemi Uruejoma
6,740 views